Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMRN

Immuron (IMRN) Stock Price, News & Analysis

Immuron logo

About Immuron Stock (NASDAQ:IMRN)

Advanced Chart

Key Stats

Today's Range
$1.85
$2.13
50-Day Range
$4.80
$5.61
52-Week Range
$1.60
$2.87
Volume
12,391 shs
Average Volume
9,222 shs
Market Capitalization
$10.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Immuron Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

IMRN MarketRank™: 

Immuron scored higher than 24% of companies evaluated by MarketBeat, and ranked 783rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immuron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immuron has received no research coverage in the past 90 days.

  • Read more about Immuron's stock forecast and price target.
  • Earnings Growth

    Earnings for Immuron are expected to decrease in the coming year, from ($0.02) to ($0.03) per share.

  • Price to Book Value per Share Ratio

    Immuron has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.31% of the float of Immuron has been sold short.
  • Short Interest Ratio / Days to Cover

    Immuron has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immuron has recently increased by 58.33%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immuron does not currently pay a dividend.

  • Dividend Growth

    Immuron does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.31% of the float of Immuron has been sold short.
  • Short Interest Ratio / Days to Cover

    Immuron has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immuron has recently increased by 58.33%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Immuron this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Immuron insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.01% of the stock of Immuron is held by insiders.

  • Percentage Held by Institutions

    Only 0.12% of the stock of Immuron is held by institutions.

  • Read more about Immuron's insider trading history.
Receive IMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter.

IMRN Stock News Headlines

Immuron reports record Travelan sales
Immuron Limited Announces New Share Issuance
The most powerful man in D.C.
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Immuron Travelan® highest sales in history
See More Headlines

IMRN Stock Analysis - Frequently Asked Questions

Immuron (IMRN) raised $6 million in an initial public offering (IPO) on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immuron investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), AbbVie (ABBV), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX).

Company Calendar

Today
4/27/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRN
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+172.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.21 million
Price / Cash Flow
N/A
Book Value
$1.46 per share
Price / Book
1.26

Miscellaneous

Free Float
5,429,000
Market Cap
$10.71 million
Optionable
Not Optionable
Beta
1.38
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:IMRN) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners